The decline in Verastem's stock price suggests that investors may have concerns about the efficacy or market potential of the Avutometinib and Defactinib combination treatment based on the updated data presented. This presentation was a significant event for the company, and the market's negative reaction indicates that the data may not have met investor expectations.